LAVA Therapeutics NV
LVTXDelisted Nov 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840748
LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 21
- Q3 2025, +2 vs. previous quarter
- 13F value
- $16.1M
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding LVTX, Q3 2025
No superinvestor reported holding LVTX at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by LAVA Therapeutics NV insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2025 (view filing)6:58 PM ET | Oct 20, 2015-Oct 17, 2025 | 3,653 daysLate | Gilde Healthcare Holding B.V. and 1 other10% Owner | SSale | −2.87M | $1.47 | −$4.22M | −59.6%1.95M after | 3 lots |
| Oct 15, 2025 (view filing)8:56 PM ET | Oct 15, 2015-Oct 14, 2025 | 3,653 daysLate | Gilde Healthcare Holding B.V. and 1 other10% Owner | SSale | −475.0K | $1.51 | −$718.7K | −9.0%4.82M after | 3 lots |
| Oct 10, 2025 (view filing)6:45 PM ET | Oct 8-10 | 2 days | Gilde Healthcare Holding B.V. and 1 other10% Owner | SSale | −127.0K | $1.56 | −$197.9K | −2.3%5.29M after | 3 lots |
| Sep 23, 2025 (view filing)4:33 PM ET | Sep 19 | 4 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −2.37M | $1.40 | −$3.32M | −100.0%0 after | |
| Sep 23, 2025 (view filing)4:33 PM ET | Sep 19 | 4 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −532.9K | $1.40 | −$746.8K | −100.0%0 after | |
| Sep 18, 2025 (view filing)6:49 PM ET | Sep 16-18 | 2 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −1.04M | $1.49 | −$1.54M | −30.4%2.37M after | 3 lots |
| Sep 18, 2025 (view filing)6:49 PM ET | Sep 16-18 | 2 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −647.8K | $1.49 | −$962.3K | −54.9%532.9K after | 3 lots |
Top 10 13F holders, Q3 2025
The largest institutional positions in LAVA Therapeutics NV at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Shay Capital LLC | 2,548,730 | $3.98M | 0.72% | +2,548,730 | New |
| Redmile Group, LLC | 2,074,372 | $3.24M | 0.31% | 00.0% | Unchanged |
| BML Capital Management, LLC | 1,970,610 | $3.07M | 2.83% | 00.0% | Unchanged |
| Sanofi | 1,919,455 | $2.99M | 1.15% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,149,345 | $1.79M | 0.79% | 00.0% | Unchanged |
| GTS Securities LLC | 200,000 | $312.0K | 0.01% | +200,000 | New |
| Rangeley Capital, LLC | 165,000 | $257.4K | 0.24% | +137,927+509.5% | Added |
| The PNC Financial Services Group, Inc. | 65,000 | $101.4K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 53,308 | $83.2K | 0.00% | +1,504+2.9% | Added |
| Royal Bank of Canada | 44,348 | $69.0K | 0.00% | +44,348 | New |
Holders of 5% or more of LVTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of LAVA Therapeutics NV.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Shay Capital LLC | 13G | 9.90%2.60M shares | New | Sep 26, 20251 filing | Sep 26, 2025 | SEC |
| BML Investment Partners, L.P. | 13G | 7.40%1.96M shares | New | Mar 3, 20251 filing | Mar 3, 2025 | SEC |